Vertex Pharma, US92532F1003

Vertex Pharma stock heads into the open after a 0.8 percent dip

Published on 09/17/2026 at 06:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

At the close on September 15, 2026, Vertex Pharma stock finished at USD 519.51 on the Nasdaq, down 0.8 percent, while the S&P 500 slipped 0.4 percent. Today, investors watch broader rate policy after the Fed raised rates at its latest meeting.

Wissenschaftler pipettiert Proben in modernem Biotech-Labor mit Automatisierungsgeräten
Vertex Pharma US92532F1003 zeigt einen Forscher im modernen Labor mit Pipette an sterilem Edelstahltisch, Illustration mit AI erstellt.

Vertex Pharma stock closed at USD 519.51 on the Nasdaq on September 15, 2026, down 0.8 percent from the prior session according to exchange data. Compared with the S&P 500, which fell 0.4 percent on September 15, 2026, the shares underperformed the wider market.

September 15, 2026 in numbers

Vertex Pharmaceuticals Inc. (ISIN US92532F1003, Nasdaq: VRTX) ended the September 15, 2026 session at USD 519.51 on the Nasdaq, a decline of USD 4.08 or 0.79 percent from a prior close of USD 523.59 per data compiled from Barrons and Nasdaq. As Ad-hoc-news reported, the move left the stock trading below the recent peak but still within its established 52-week range. On the same day, the S&P 500 closed at 7,551.81, down 33.92 points or 0.4 percent, highlighting that broader United States equities also lost ground, as summarized by KRMG. Day range and volume figures for Vertex on September 15, 2026 were consistent with recent trading, with the closing price sitting between the intraday high and low and within the stock's 52-week band.

Fed decision and conference participation today

Today, Vertex Pharma shares face the open against a backdrop of tighter monetary policy after the Federal Reserve unanimously raised interest rates at its latest meeting, a move that weighed on United States stocks according to an audio market wrap from Bloomberg. In addition, Vertex is set to take part in the Bank of America Global Healthcare Conference on September 23, 2026, an event flagged in the company calendar on MarketBeat, which may offer fresh commentary for investors ahead of the next earnings release in November.

Disclaimer...

en | US92532F1003 | VERTEX PHARMA | boerse | 70114556 | bgmi